Compare NPCE & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPCE | FLGT |
|---|---|---|
| Founded | 1997 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.2M | 511.0M |
| IPO Year | 2021 | 2016 |
| Metric | NPCE | FLGT |
|---|---|---|
| Price | $14.69 | $19.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | $18.33 | ★ $28.33 |
| AVG Volume (30 Days) | 163.9K | ★ 223.8K |
| Earning Date | 05-12-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,986,000.00 | $18,730,000.00 |
| Revenue This Year | $0.90 | $10.09 |
| Revenue Next Year | $24.46 | $12.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.13 | N/A |
| 52 Week Low | $9.22 | $13.46 |
| 52 Week High | $19.60 | $31.04 |
| Indicator | NPCE | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 51.45 | 54.14 |
| Support Level | $13.74 | $19.20 |
| Resistance Level | $15.27 | $20.24 |
| Average True Range (ATR) | 0.59 | 0.54 |
| MACD | 0.10 | 0.07 |
| Stochastic Oscillator | 66.86 | 66.52 |
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.